1. Home
  2. ZYME vs PDM Comparison

ZYME vs PDM Comparison

Compare ZYME & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • PDM
  • Stock Information
  • Founded
  • ZYME 2003
  • PDM 1997
  • Country
  • ZYME United States
  • PDM United States
  • Employees
  • ZYME N/A
  • PDM N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • PDM Building operators
  • Sector
  • ZYME Health Care
  • PDM Real Estate
  • Exchange
  • ZYME Nasdaq
  • PDM Nasdaq
  • Market Cap
  • ZYME 968.5M
  • PDM 948.7M
  • IPO Year
  • ZYME 2017
  • PDM N/A
  • Fundamental
  • Price
  • ZYME $12.43
  • PDM $7.80
  • Analyst Decision
  • ZYME Buy
  • PDM Buy
  • Analyst Count
  • ZYME 7
  • PDM 5
  • Target Price
  • ZYME $19.50
  • PDM $9.40
  • AVG Volume (30 Days)
  • ZYME 409.0K
  • PDM 823.0K
  • Earning Date
  • ZYME 08-07-2025
  • PDM 07-28-2025
  • Dividend Yield
  • ZYME N/A
  • PDM 6.38%
  • EPS Growth
  • ZYME N/A
  • PDM N/A
  • EPS
  • ZYME N/A
  • PDM N/A
  • Revenue
  • ZYME $93,384,000.00
  • PDM $565,502,000.00
  • Revenue This Year
  • ZYME $44.71
  • PDM $0.50
  • Revenue Next Year
  • ZYME $34.57
  • PDM N/A
  • P/E Ratio
  • ZYME N/A
  • PDM N/A
  • Revenue Growth
  • ZYME 85.05
  • PDM N/A
  • 52 Week Low
  • ZYME $9.03
  • PDM $5.46
  • 52 Week High
  • ZYME $17.70
  • PDM $11.12
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 40.44
  • PDM 59.11
  • Support Level
  • ZYME $12.26
  • PDM $7.24
  • Resistance Level
  • ZYME $13.80
  • PDM $7.65
  • Average True Range (ATR)
  • ZYME 0.62
  • PDM 0.24
  • MACD
  • ZYME -0.21
  • PDM 0.02
  • Stochastic Oscillator
  • ZYME 10.19
  • PDM 88.97

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About PDM Piedmont Office Realty Trust Inc.

Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.

Share on Social Networks: